Protocols · MSK/Tissue Repair
BPC-157 Gastrointestinal Healing Protocol
Pentadecapeptide Cytoprotectant | GI Mucosal Healing & IBD Adjunct
Typical Dose
500 mcg BID
Oral; SC adjunct 250-500 mcg daily for transmural disease
Route
Oral + SC
Oral for luminal pathology, SC for systemic/transmural
Cycle
6-12 weeks
Acute / consolidation / taper phases; 8 on / 4 off if maintenance
Storage
Refrigerate 2-8°C
Reconstituted vial stable ~30 days refrigerated; lyophilized vial stable longer frozen
Patient version available. Share ?view=patient with patients for the plain-language handout.
Overview
This protocol targets restoration of gastrointestinal mucosal integrity in patients with established or suspected epithelial barrier dysfunction. Clinical scenarios include NSAID-induced gastropathy, mild-to-moderate inflammatory bowel disease (as an adjunct to standard therapy), post-infectious IBS with persistent permeability, anastomotic healing support, and reflux-associated esophagitis refractory to PPI monotherapy. The protocol is designed to be deployed as a 6-12 week intervention with re-evaluation, not as chronic indefinite therapy.
BPC-157 (Body Protection Compound-157), a pentadecapeptide derived from a partial sequence of human gastric juice protein, is the sole agent in this stack. The single-peptide approach reflects both the breadth of BPC-157's documented effects across the GI tract and the desire to isolate a clinical signal in a registry setting. Oral dosing delivers locally to gastric and intestinal mucosa; subcutaneous dosing achieves systemic exposure for more distal or transmural pathology.
The clinical goal is twofold: (1) accelerate epithelial restitution and reduce mucosal inflammation in the affected segment, and (2) reduce symptom burden (pain, bleeding, diarrhea, dyspepsia) sufficiently to allow taper or de-escalation of background pharmacotherapy where clinically appropriate.
Key Benefits
Accelerates restitution of gastric and intestinal epithelium, reduces mucosal inflammation, and supports symptom control in NSAID gastropathy, IBD, and post-infectious IBS.
Mechanism of Action
Upregulates VEGFR2-driven angiogenesis, restores tight junction integrity (ZO-1, occludin), and modulates nitric oxide and growth factor pathways to protect and repair GI epithelium.
Molecular Information
Weight
1419.5 Da
Length
15 amino acids
Type
Pentadecapeptide
Amino Acid Sequence
Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val
* Partial sequence derived from human gastric juice protein
Pharmacokinetics
Research Indications
NSAID GastropathyEFFECTIVE
Symptomatic relief
Dyspepsia and epigastric pain commonly improve within 7-14 days of oral dosing.
Mucosal protection
Preclinical models show consistent prevention and healing of NSAID-induced gastric lesions.
Inflammatory Bowel DiseaseEMERGING
Adjunct to standard care
May support biomarker reduction (calprotectin, CRP) and symptom control alongside guideline-directed therapy.
Transmural disease
SC route used empirically for fistulizing or perianal Crohn's; evidence is preclinical and anecdotal.
Post-Infectious IBSEMERGING
Barrier restoration
Targets persistent epithelial permeability following infectious insult.
Bowel pattern stability
Patients commonly report stabilization of stool frequency and consistency by week 8.
Peptic Ulcer / EsophagitisEMERGING
Refractory reflux
Used empirically for esophagitis incompletely controlled on PPI monotherapy.
Ulcer healing
Confirm H. pylori status before initiation; treat underlying cause.
Anastomotic / Post-Surgical HealingEMERGING
Preclinical signal
Rodent models show improved anastomotic strength and reduced leak rates.
Human data
No published RCT evidence; use considered empirical.
Research Protocols
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| Acute phase (Wk 1-4) | 500 mcg | PO BID | Oral |
| Transmural adjunct | 250-500 mcg | Once daily | Subcutaneous |
| Severe flare (empirical) | Up to 750 mcg | BID | Oral + SC |
| Consolidation (Wk 5-8) | 250-500 mcg | PO BID | Oral |
| Taper (Wk 9-12) | 250 mcg | PO daily or BID 5d/wk | Oral |
| Maintenance cycling | 250-500 mcg | 8 wk on / 4 wk off | Oral |
Timing · Oral dosing on empty stomach or with light food. SC injections rotated between abdomen and thigh; some clinicians inject near affected segment as empirical practice.
Peptide Interactions
- KPV— Complementary anti-inflammatory action on gut mucosa; commonly co-administered for IBD.SYNERGISTIC
- Larazotide— Tight junction modulation pairs with epithelial restitution effects.SYNERGISTIC
- TB-500— Often combined for broader tissue repair, including transmural disease.SYNERGISTIC
- LL-37— Antimicrobial adjunct in SIBO or dysbiosis-driven gut pathology.COMPATIBLE
- Corticosteroids— Anecdotal potentiation of taper tolerance; watch for HPA-axis effects with rapid weaning.MONITOR
- NSAIDs— May mitigate but does not eliminate gastropathy risk; do not enable unrestricted NSAID use.MONITOR
- Anti-angiogenic oncology agents— Theoretical antagonism via VEGFR2 pathway; avoid co-administration.AVOID
- GHK-Cu— Compatible regenerative agent; no documented interaction.COMPATIBLE
How to Reconstitute
- 1
Gather 10 mg lyophilized vial, bacteriostatic water, alcohol swabs, and appropriate syringes.
- 2
Wash hands and sanitize the work surface.
- 3
Wipe both vial stoppers (peptide and BAC water) with fresh alcohol swabs.
- 4
Draw 2-5 mL of bacteriostatic water based on desired concentration (e.g., 2 mL = 5 mg/mL).
- 5
Inject the diluent slowly down the inside wall of the vial — do not jet directly onto the powder.
- 6
Swirl gently until fully dissolved. Do not shake vigorously.
- 7
Inspect the solution — it should be clear and colorless with no particulates.
- 8
Label the vial with reconstitution date, concentration, and route.
- 9
Store reconstituted vial refrigerated at 2-8°C.
- 10
For oral use, draw the dose into an oral syringe and administer directly or dilute in a small volume of water.
- 11
For SC injection, use an insulin syringe and rotate sites between abdomen and thigh.
- 12
Discard the vial after 30 days or sooner if cloudiness or discoloration appears.
Quality Indicators
Clear solution
Reconstituted peptide should be water-clear with no visible particulates or color.
Full dissolution
Powder dissolves completely within 1-2 minutes of gentle swirling.
Cloudy or hazy appearance
May indicate degradation, contamination, or incorrect diluent — do not use.
Particulate matter or discoloration
Discard immediately; potency and sterility cannot be assured.
What to Expect
Week 1-2: Symptomatic improvement in dyspepsia, epigastric pain, or stool frequency for many patients.
Week 2: Mild nausea or altered appetite in first week of oral dosing typically resolves.
Week 4: Clinical check and symptom diary review; biomarkers often unchanged at this point.
Week 6-8: Measurable reductions in fecal calprotectin and hs-CRP expected in responders.
Week 8: Post-infectious IBS patients often report stabilization of bowel pattern.
Week 10-12: Endoscopic/mucosal healing endpoints become assessable.
Week 12: Responders typically show 40-70% symptom score reduction and biomarker improvement.
Non-responders by week 12 should prompt diagnostic reassessment, not extended monotherapy.
Side Effects & Safety
- Injection-site erythema or transient soreness (SC route)
- Mild nausea or altered appetite in first week of oral dosing
- Transient fatigue or flu-like sensation (anecdotal)
- Headache
- Rare palpitations or transient blood pressure changes
- Local irritation at injection sites with rotation lapse
When to Stop & Call Provider
- New or worsening malignancy concern
- Severe or persistent palpitations or hypertensive episodes
- Allergic or hypersensitivity reaction (rash, swelling, dyspnea)
- Confirmed pregnancy
- GI bleeding or significant clinical deterioration despite therapy
- Vision changes in patients with retinopathy history
References
Sikiric P et al. — Stable Gastric Pentadecapeptide BPC 157 and Wound Healing
Comprehensive review of BPC-157 mechanisms across GI healing models, including VEGFR2 signaling, NO pathway involvement, and growth factor receptor modulation. Synthesizes data from rodent gastric ulcer, colitis, and anastomotic models.
Sikiric P et al. — BPC 157 and Standard Angiogenic Growth Factors
Demonstrates BPC-157's upregulation of VEGFR2 and downstream angiogenic signaling as the mechanistic basis for accelerated mucosal repair across multiple tissue types.
Sikiric P et al. — Pentadecapeptide BPC 157 in Experimental Colitis Models
BPC-157 reduces histologic inflammation and accelerates mucosal healing in DSS and TNBS rodent colitis models, with effects observed via both oral and parenteral routes.
Sikiric P et al. — BPC 157 Counteracts NSAID-Induced Injury
Pretreatment and rescue dosing with BPC-157 attenuates NSAID-induced gastric, intestinal, and hepatic injury in rodent models, supporting clinical use as an adjunct in NSAID-associated mucosal disease.